Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders
Autore:
Breier, A; Su, TP; Malhotra, AK; Elman, I; Adler, CM; Weisenfeld, NI; Pickar, D;
Indirizzi:
NIMH, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA NIMH Bethesda MDUSA 20892 Therapeut Branch, NIH, Bethesda, MD 20892 USA NIMH, Intramural Res Program, NIH, Bethesda, MD 20892 USA NIMH Bethesda MD USA 20892 mural Res Program, NIH, Bethesda, MD 20892 USA
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 4, volume: 20, anno: 1999,
pagine: 340 - 345
SICI:
0893-133X(199904)20:4<340:EOAADT>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
D2-DOPAMINE RECEPTOR OCCUPANCY; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIC-PATIENTS; C-11 RACLOPRIDE; FOS EXPRESSION; C-FOS; CLOZAPINE; NEURONS; RISPERIDONE; HALOPERIDOL;
Keywords:
clozapine; risperidone; positron emission tomography; raclopride; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Breier, A Eli Lilly & Co, Lilly Corp Ctr, Drop Code 0538, Indianapolis, IN46285 USA Eli Lilly & Co Drop Code 0538 Indianapolis IN USA 46285 6285 USA
Citazione:
A. Breier et al., "Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders", NEUROPSYCH, 20(4), 1999, pp. 340-345

Abstract

Clozapine, risperidone, and other new "atypical" antipsychotic agents are distinguished from traditional neuroleptic drugs by having clinical efficacy with either no or low levels of extrapyramidal symptoms (EPS). Preclinical models have focused on striatal dopamine systems to account for their atypical profile. In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders. A novel C-11-raclopride/PET paradigm was used to deriveestimates of amphetamine-induced changes in striatal synaptic dopamine concentrations and patients were scanned while antipsychotic drug-free and during chronic treatment with either clozapine or risperidone. We found that amphetamine produced significant reductions in striatal C-11-raclopride binding during the drug-free and antipsychotic drug treatment phases of the study which reflects enhanced dopamine release in both conditions. There were no significant differences in % C-11-raclopride changes between the two conditions indicating that these atypical agents do not effect amphetamine-related striatal dopamine release. The implications for these data for antipsychotic drug action are discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 04:57:57